Harrow (NASDAQ:HROW – Get Free Report) and Merck KGaA (OTCMKTS:MKKGY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
72.8% of Harrow shares are owned by institutional investors. Comparatively, 0.1% of Merck KGaA shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings for Harrow and Merck KGaA, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harrow | 2 | 1 | 6 | 0 | 2.44 |
| Merck KGaA | 0 | 6 | 0 | 0 | 2.00 |
Harrow presently has a consensus target price of $66.20, suggesting a potential upside of 117.69%. Given Harrow’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Harrow is more favorable than Merck KGaA.
Profitability
This table compares Harrow and Merck KGaA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harrow | -9.39% | -69.81% | -5.16% |
| Merck KGaA | 8.95% | 6.53% | 3.68% |
Risk & Volatility
Harrow has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Valuation & Earnings
This table compares Harrow and Merck KGaA”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harrow | $272.30 million | 4.19 | -$5.14 million | ($0.78) | -38.99 |
| Merck KGaA | $23.87 billion | 0.86 | $2.95 billion | $1.37 | 23.24 |
Merck KGaA has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Merck KGaA, indicating that it is currently the more affordable of the two stocks.
Summary
Merck KGaA beats Harrow on 7 of the 13 factors compared between the two stocks.
About Harrow
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
About Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
